CRISPR Therapeutics' CTX310 Shows Durable Lipid-Lowering Effects in Phase 1a Trial
Event summary
- CRISPR Therapeutics presented Phase 1a data for CTX310 at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose.
- The therapy was well tolerated with no treatment-related serious adverse events and sustained effects through one year of follow-up.
- The data were simultaneously published in The New England Journal of Medicine.
- CRISPR Therapeutics is advancing CTX310 in a Phase 1b clinical trial, with updates expected in the second half of 2026.
The big picture
CRISPR Therapeutics' Phase 1a data for CTX310 represent a significant milestone in the development of one-time gene editing therapies for cardiometabolic diseases. The durable reductions in ANGPTL3, triglycerides, and LDL after a single infusion highlight the potential of CRISPR/Cas9 gene editing to address lifelong lipid disorders. The company's broader cardiovascular gene editing portfolio, including programs targeting hypertension and lipoprotein(a), positions it as a key player in the evolving landscape of genetic medicines.
What we're watching
- Clinical Progress
- Whether the Phase 1b trial results will confirm the durability and safety of CTX310 in severe hypertriglyceridemia patients.
- Regulatory Pathway
- The pace at which CRISPR Therapeutics can advance CTX310 through subsequent clinical trials and potential regulatory approval.
- Competitive Landscape
- How CRISPR Therapeutics' in vivo gene editing platform will position it against other cardiovascular disease treatments.
Related topics